help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 Click here to read this article as a CME course

First Published Online January 14, 2009
The Oncologist, Vol. 14, No. 1, 40-51, January 2009; doi:10.1634/theoncologist.2008-0123
© 2009 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
theoncologist.2008-0123v1
14/1/40    most recent
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thurairaja, R.
Right arrow Articles by Burkhard, F. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thurairaja, R.
Right arrow Articles by Burkhard, F. C.

Genitourinary Cancer

Indications, Extent, and Benefits of Pelvic Lymph Node Dissection for Patients with Bladder and Prostate Cancer

Ramesh Thurairaja, Urs E. Studer, Fiona C. Burkhard

Urology Department, Inselspital, Bern, Switzerland

Key Words. Extended pelvic lymph node dissection • Bladder cancer • Prostate cancer

Correspondence: Fiona Burkhard, M.D., Urology Department, Anna Seiler Haus, Inselspital, 3010 Bern, Switzerland. Telephone: 0041-316322111; Fax: 0041-316322180; e-mail: fiona.burkhard{at}insel.ch

Received May 27, 2008; accepted for publication December 7, 2008; first published online in THE ONCOLOGIST Express on January 14, 2009.

Disclosures

Ramesh Thurairaja: None; Urs E. Studer: None; Fiona C. Burkhard: Consultant/advisory role: Medtronic

Section editors Chris Parker and Matthew R. Smith have disclosed no financial relationships relevant to the content of this article.

The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias.

Target audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in genitourinary cancer.

The role of pelvic lymph node dissection (PLND) in both bladder and prostate cancer has recently been generating renewed interest. In an attempt to avoid PLND, both nomograms and imaging studies have been evaluated; however, so far they have shown limited success because of inadequate accuracy in staging patients. The three primary objectives of this review are: to define patients in whom PLND should be performed, to define the extent and consequences of the template for PLND, and to identify the staging and prognostic benefits seen with PLND in bladder and prostate cancer. Based on the findings from this review, we conclude that PLND for bladder cancer patients is undoubtedly beneficial, whereas it is less so for prostate cancer patients, in whom a selection strategy should be employed. PLND, in particular with an extended template, seems to provide superior accuracy for postoperative staging than the presently available imaging studies and may be pivotal when considering adjuvant therapies. Furthermore, it has an impact on survival in high-risk patients, and potentially more so in low-risk cancer patients with occult metastases.






HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2009 by AlphaMed Press.